Clinical Trials Logo
  1. Home
  2. Thymidine Kinase 2 Deficiency
  3. NCT03845712

An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency — Continuation  

Thymidine Kinase 2 Deficiency Clinical Trial

Official title:
A Phase 2 Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With Thymidine Kinase 2 Deficiency (TK2)

Clinical Trial Summary

This is a Phase 2 prospective open-label treatment study of the safety and efficacy of doxecitine and doxribtimine in study participants with thymidine kinase 2 (TK2) deficiency who participated in the retrospective study MT-1621-101 [NCT03701568] or who were receiving nucleos(t)ide treatment and were approved by the Sponsor.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03845712
Study type Interventional
Source UCB Pharma
Contact
Status Active, not recruiting
Phase Phase 2
Start date July 5, 2019
Completion date June 18, 2025
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT04581733 - A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) Phase 3
Active, not recruiting NCT03639701 - Treatment of TK2 Deficiency With Thymidine and Deoxycytidine Phase 1/Phase 2
Completed NCT05017818 - A Retrospective Study of Subjects With Thymidine Kinase 2 Deficiency